Objective: To describe tardive rebound anxiety phenomena (panic, anxiety and insomnia) following abrupt paroxetine discontinuation.
Method: Case report, with comprehensive literature review on rebound and withdrawal phenomena associated with psychotropic medications.
Results: Three different discontinuation syndromes with psychotropics are described: (1) new-onset CNS-depressant type withdrawal symptoms (minor and major); (2) rebound syndromes; and (3) supersensitivity symptoms. Abrupt paroxetine discontinuation has been well described and fits the first category. Tardive rebound panic disorder-phenomena with paroxetine has some features of the supersensitivity category.
Conclusion: Chronic paroxetine treatment may lead to 5-HT2-receptor down regulation, with desensitization of 5-HT1A and 5-HT2 receptors, which may contribute to tardive rebound symptoms upon abrupt withdrawal. Early reports suggest that genetic factors may also contribute to withdrawal symptoms in susceptible individuals. Cholinergic rebound may also occur and could explain tardive insomnia and anxiety in paroxetine withdrawal.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Management of Cholinergic Rebound After Abrupt Withdrawal of Clozapine: A Case Report and Systematic Literature Review.
J Acad Consult Liaison Psychiatry
August 2024
Northwell Health, Long Island Jewish Medical Center, New Hyde Park, NY.
Background: Cholinergic discontinuation symptoms, also known as "cholinergic rebound," from abrupt clozapine discontinuation are characterized by a range of somatic and psychiatric symptoms.
Objective: The objective of this study was to describe the clinical features and management options for clozapine withdrawal-associated cholinergic rebound syndrome (henceforth referred to as CWCRS) and present an illustrative case report.
Methods: Based on a literature search of the databases PubMed, OVID Medline, and Embase as well as reviewing reference lists of relevant past reviews, we carried out a systematic review of case reports on the management of CWCRS from 1946 to 2023.
Non-Psychosis Symptoms of Clozapine Withdrawal: a Systematic Review.
East Asian Arch Psychiatry
June 2023
Department of Medicine, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.
Article Synopsis
- Clozapine is an effective antipsychotic used for schizophrenia that can cause various withdrawal symptoms, particularly when discontinued.* -
- A review analyzing five studies found that about 20% of patients reported non-psychosis symptoms after stopping clozapine, including cholinergic rebound and extrapyramidal symptoms.* -
- Clinicians need to recognize these withdrawal symptoms for timely treatment, and more research is needed to understand their prevalence and best management strategies.*
The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia.
CNS Spectr
June 2020
Warwick Medical School, University of Warwick, Coventry, United Kingdom.
This is a report of a joint World Psychiatric Association/International College of Neuropsychopharmacology (WPA/CINP) workgroup concerning the risk/benefit ratio of antipsychotics in the treatment of schizophrenia. It utilized a selective but, within topic, comprehensive review of the literature, taking into consideration all the recently discussed arguments on the matter and avoiding taking sides when the results in the literature were equivocal. The workgroup's conclusions suggested that antipsychotics are efficacious both during the acute and the maintenance phase, and that the current data do not support the existence of a supersensitivity rebound psychosis.
View Article and Find Full Text PDFBrexpiprazole has a low risk of dopamine D receptor sensitization and inhibits rebound phenomena related to D and serotonin 5-HT receptors in rats.
Neuropsychopharmacol Rep
December 2019
Department of CNS Research, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan.
Background: Long-term antipsychotic treatment in patients with schizophrenia can induce supersensitivity psychosis and tardive dyskinesia which is thought to be caused by dopamine D receptor sensitization. We evaluated the effects of brexpiprazole on D receptor sensitivity after subchronic treatment in rats. We also evaluated whether brexpiprazole could suppress enhanced response to D receptors in rats subchronically dosed with another atypical antipsychotic.
View Article and Find Full Text PDFDopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice.
J Psychopharmacol
December 2017
1 Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan.
Dopamine supersensitivity psychosis (DSP) is observed in patients with schizophrenia under antipsychotic treatment, and it is characterized by rebound psychosis, an uncontrollable psychotic episode following a stable state and tardive dyskinesia. DSP, first described in patients taking typical antipsychotics in the late 1970s, sometimes appears even in patients who are treated with current atypical antipsychotics. It was recently demonstrated that DSP can have a negative impact on the long-term prognosis of schizophrenia patients and that DSP could be involved in the etiology of some cases of treatment-resistant schizophrenia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!